Does Low-Dose Radiation Help Arthritis? A Balanced Evidence Review

Short answer: Low-dose radiotherapy may reduce osteoarthritis pain for some carefully selected patients, but the research is mixed. A positive 2025 sham-controlled knee trial and 2026 expert criteria strengthen the case for selected use, while older negative sham trials and a 2025 meta-analysis argue against broad claims or routine use for everyone.

Why simple “success rates” are misleading

An arthritis study may define success as:

• a minimum change in pain score;
• improvement in function;
• reduced medication;
• a combined responder definition;
• patient-reported “better” or “much better”; or
• avoiding another procedure.

A 70% response in one study may not measure the same outcome as 70% in another. Results also depend on who was offered treatment and when they were assessed.

What observational studies suggest

Large retrospective series, especially from Europe, often report pain improvement in a majority of treated patients. These data are useful for understanding real-world technique and uncommon short-term side effects.

They have important limitations:

• patients and clinicians know treatment was given;
• people selected for radiation may differ from those who were not;
• pain naturally fluctuates;
• co-treatments may change; and
• people who improve may be more likely to return or report outcomes.

Observational response rates should therefore generate useful estimates and hypotheses—not individualized guarantees.

What did earlier sham-controlled trials find?

A Dutch randomized, double-blind, sham-controlled knee trial published in 2019 found no substantial difference in responders between low-dose radiotherapy and sham treatment. Other sham-controlled work also failed to demonstrate clear benefit.

Critics have questioned whether some negative studies used optimal patient selection, timing, or treatment protocols. Those critiques may be reasonable, but a negative randomized result cannot be dismissed simply because it conflicts with clinical experience.

What changed in 2025?

A multicenter Korean trial randomized 114 people with mild-to-moderate knee osteoarthritis to 3 Gy, 0.3 Gy, or sham treatment over six visits.

At four months, 70.3% in the 3 Gy group met the OMERACT-OARSI response definition, compared with 41.7% after sham. The 0.3 Gy arm was not significantly different from sham. No treatment-related toxicity was reported in the short follow-up.

This is an important positive randomized result. It remains one modest-sized trial, initially reported at a conference, with longer follow-up pending.

What did the 2025 meta-analysis conclude?

A systematic review included 12 studies with 1,750 participants; six were eligible for meta-analysis. It found:

• no statistically significant pain benefit over sham;
• no statistically significant functional benefit over sham;
• more overall adverse events; and
• more nail reactions in treated groups.

The authors concluded that evidence did not support LDRT over standard therapies and suggested reserving it for research or selected refractory cases.

Meta-analyses are not automatically the final word. Combining clinically different joints, regimens, and populations can obscure a benefit limited to a particular subgroup. Still, this review is a significant counterweight to promotional claims.

How do the 2026 ARS criteria fit?

The American Radium Society used a structured multidisciplinary process and concluded that low-dose radiotherapy can be an evidence-based option in appropriate scenarios. Its review cited overall response rates of 60% to 90% but also called for more high-quality studies.

The criteria and meta-analysis ask somewhat different questions. One evaluates appropriateness across clinical scenarios using evidence plus expert consensus; the other statistically combines selected outcomes. Their disagreement is a reason for transparent shared decision-making.

A reasonable evidence-based position

Based on current evidence:

• low-dose radiotherapy should not be promised to work;
• it should not replace diagnosis or standard first-line care;
• selected older adults with confirmed, persistent osteoarthritis may reasonably discuss it;
• expected benefit should be defined before treatment; and
• lack of response should prompt reassessment rather than automatic repetition.

Patients deserve to hear both the supportive and negative evidence. A balanced explanation is not a weakness—it is essential to informed consent.

Questions patients often ask

Why do studies reach different conclusions?

They differ in joint, dose, disease severity, age, allowed medication, outcome definition, follow-up, and study design. Unblinded observational studies are also more susceptible to placebo and selection effects.

Is low-dose radiotherapy experimental in the United States?

Use is increasing and professional criteria now address it, but evidence and adoption remain less established than many standard osteoarthritis treatments. Patients should ask about local practice, coverage, alternatives, and uncertainty.

Can radiation rebuild cartilage?

No evidence shows that low-dose radiotherapy restores lost cartilage. The proposed benefit is symptom reduction through anti-inflammatory effects.

Sources and further reading

1. Efficacy, safety, and pain management of low-dose radiation therapy in osteoarthritis. Rheumatology International (2025).
2. Effectiveness of low-dose radiation therapy on symptoms in knee osteoarthritis. Annals of the Rheumatic Diseases (2019).
3. Clinical Effectiveness of Low-Dose Radiation Therapy in Knee Osteoarthritis. ASTRO Annual Meeting (2025).
4. American Radium Society Appropriate Use Criteria for Low-Dose Radiotherapy for Osteoarthritis. American Journal of Clinical Oncology (2026).